Mayne Pharma Group Limited
MAYNF
$3.29
-$0.23-6.54%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 272.77M | 264.59M | 254.74M | 188.68M | 122.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 272.77M | 264.59M | 254.74M | 188.68M | 122.77M |
| Cost of Revenue | 111.91M | 111.89M | 111.25M | 82.43M | 53.66M |
| Gross Profit | 160.86M | 152.69M | 143.49M | 106.26M | 69.10M |
| SG&A Expenses | 155.05M | 157.67M | 159.34M | 123.52M | 87.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 280.07M | 282.79M | 283.86M | 215.93M | 148.13M |
| Operating Income | -7.30M | -18.21M | -29.12M | -27.24M | -25.37M |
| Income Before Tax | -85.58M | -105.18M | -124.76M | -86.79M | -48.91M |
| Income Tax Expenses | -7.82M | -10.94M | -14.11M | -8.46M | -2.82M |
| Earnings from Continuing Operations | -77.76 | -94.24 | -110.65 | -78.33 | -46.09 |
| Earnings from Discontinued Operations | -7.38M | -5.56M | -3.70M | -1.85M | -2.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.14M | -99.80M | -114.34M | -80.18M | -46.09M |
| EBIT | -7.30M | -18.21M | -29.12M | -27.24M | -25.37M |
| EBITDA | 32.17M | 22.62M | 12.83M | 4.84M | -3.14M |
| EPS Basic | -1.08 | -1.26 | -1.44 | 0.15 | 1.74 |
| Normalized Basic EPS | -0.15 | -0.26 | -0.37 | -0.32 | -0.28 |
| EPS Diluted | -1.08 | -1.26 | -1.44 | 0.15 | 1.74 |
| Normalized Diluted EPS | -0.15 | -0.26 | -0.37 | -0.32 | -0.28 |
| Average Basic Shares Outstanding | 315.94M | 317.21M | 318.48M | 321.77M | 242.89M |
| Average Diluted Shares Outstanding | 315.94M | 317.21M | 318.48M | 321.77M | 325.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |